Search Here

Search for:

Skip to primary navigation
Skip to main content
Skip to footer

The Desmoid Tumor Research Foundation

Donate
Contact
Search

Skip Navigation

About Desmoid Tumors
- About Desmoid Tumors
- What is a Desmoid Tumor?
- Diagnosis
- Treatment & Monitoring
- Glossary
- FAQs
- Helpful Links
Patients & Caregivers
Clinicians & Researchers
Research
Get Involved
About DTRF
Video Library

A phase 1/2 trial of FOG-001, a first-in-class direct β-catenin:TCF inhibitor safety and preliminary antitumor activity in patients with desmoid tumors

Home About DTRF News & Updates A phase 1/2 trial of FOG-001, a first-in-class direct β-catenin:TCF inhibitor safety and preliminary antitumor activity in patients with desmoid tumors

November 18, 2025 by

Stay Up to Date as We Uncover More About Desmoid Tumors

Join The DTRF Newsletter

Join the Clinicians & Researchers Newsletter

Your Donation Changes Lives

Every donation, no matter the size, helps us continue our mission.

Footer

About Desmoid Tumors
Patients & Caregivers
Clinicians & Researchers
Research
Get Involved
About DTRF

Connect With Us

Facebook Vimeo Twitter Flickr LinkedIn Instagram

© Desmoid Tumor Research Foundation (DTRF) | c/o CliftonLarsonAllen LLP, 50 Tice Blvd, Suite 175, Woodcliff Lake, NJ 07677
Registered 501(c)(3). EIN: 61-1493017

Privacy Policy
State Disclosures
Terms of Use
Cookie Policy

About Desmoid Tumors
Patients & Caregivers
Clinicians & Researchers
Research
Get Involved
About DTRF
Video Library
Contact Us